Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients — Stella

Home/Alzheimer's Disease/

View on ClinicalTrials.gov

Recruiting

Back to Alzheimer's Disease trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

The First Affiliated hospital of USTC, Hefei, Anhui

Key details

Phase

Safety & dosing

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.

Enrollment target

~45 participants

Started

February 2024

Primary completion

April 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

50 Years – 85 Years

Last updated April 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.